China SXT Pharmaceuticals (SXTC): Price to Earnings Adjusted for Growth Rate
Geopolitical tensions and export bans are limiting the expansion of China SXT Pharmaceuticals (SXTC) beyond the PRC. A narrow profile in traditional medicine ties revenues to local standards. Nevertheless, China SXT Pharmaceuticals (SXTC) is modernizing its laboratories to capture the domestic market. The PEG ratio reflects the business valuation dynamics, where 0.00 indicates the level of this metric.
Metric breakdowns and analytics for SXT Pharmaceuticals (SXTC)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Capital China SXT Pharmaceuticals|SXTC - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital China SXT Pharmaceuticals, Inc.|SXTC - Company Aggregate Debts|Debt to Book Value SXTC|SXTC - Company Long-Term Debts|Company Short-Term Loans and Borrowings China SXT Pharmaceuticals|Interim Coverage Ratio sxtchina.com
- earnings and market ratios statistics:
SXTC - Company Net Income|Net Profit Forecast China SXT Pharmaceuticals|SXTC - P/E Multiple|Forward P/E Multiple SXT China|SXTC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation China SXT Pharmaceuticals|SXTC - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters China SXT Pharmaceuticals|SXTC - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months sxtchina.com|SXTC - Net earnings per share growth this year|Projected earnings per share increase next year China SXT Pharmaceuticals
- issuer revenue and sales details:
General company analysis:SXTC (SXT China)
The PEG ratio compares the market value of earnings to their growth rate, where a value below one signals a fundamental undervaluation of the asset. By analyzing the PEG multiple, an investor assesses the capitalization efficiency of China SXT Pharmaceuticals (SXTC), whose vertical integration within the traditional medicine sector creates sustainable profit potential through total control over product quality.
Competing companies
HLN - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Kenvue Inc KVUE|Verona Pharma (VRNA) - Price to Earnings Adjusted for Growth Rate|MENS: Price/Earnings to Growth Multiple|Ligand - Company Value to Earnings Growth Ratio|AMRX: PEG Multiple|Perrigo Company - Growth-Adjusted Payback Ratio|ALVO (Alvotech S.A.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate liquidia.com LQDA|Price/Earnings to Growth Ratio Galapagos (GLPG)|ANIP (ANI Pharmaceuticals, Inc.) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Afrezza MNKD|PEG Multiple Amphastar Corp AMPH|Pacira Corp - PEG Multiple|Growth-Adjusted Payback Ratio SPRY (ars-pharma.com)|TBPH: PEG Multiple|Aquestive Therapeutics, Inc. (AQST) - PEG Multiple|SCPH (scpharmaceuticals.com) - PEG Multiple|TECX (tectonictx.com) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple TNXP (Tonix Pharmaceuticals Holding Corp.)|PEG Multiple Eupraxia Pharma (EPRX)|Price/Earnings to Growth Ratio BioHarvest Sciences Inc. BHST|EXOZ - Price/Earnings to Growth Multiple|ORMP: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ENTX (enterabio.com)|MindWalk Therapeutics (HYFT) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate abvcpharma.com (ABVC)|Price/Earnings to Growth Ratio Cumberland Pharma|Price/Earnings to Growth Ratio QNTM|PEG Multiple FGEN|TELO (Telomir Pharma) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Rani Therapeutics Holdings RANI|SNYR - Price/Earnings to Growth Multiple|RLYB - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income lexariabioscience.com LEXX|PULM: PEG Multiple|Growth-Adjusted P/E Ratio PTHL|Price/Earnings to Growth Ratio Aptorum Group Limited|LYRA (Lyra Therapeutics, Inc.) - Company Value to Earnings Growth Ratio|PEG Multiple IBO|Growth-Adjusted Market Cap to Net Income TNF Pharmaceuticals, Inc.|PEG Multiple YCBD (cbdMD, Inc.)|PRFX (PainReform Corp) - Market Cap to Earnings and Growth Ratio|CYTO: Price/Earnings to Growth Multiple|LIPO - PEG Multiple|OptiNose, Inc. (OPTN) - Price/Earnings to Growth Ratio|PIRS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Procaps|Price/Earnings to Growth Multiple Petros (PTPI)|Price/Earnings to Growth Ratio Qilian International Corp (QLI)|PEG Multiple acelyrin.com (SLRN)|PEG Multiple TFFP (TFF Pharmaceuticals)
